NCT04000282 - First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

August 29, 2022

Study Completion Date

September 4, 2023

Conditions

Plasma Cell Myeloma

Interventions

DRUG

SAR442085

Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous

Trial Locations (12)

Investigational Site Number : 1580001, Taipei

Investigational Site Number : 3000001, Athens

Investigational Site Number : 2030001, Prague

UNC Chapel Hill Site Number : 8400006, Chapel Hill

Investigational Site Number : 2500001, Toulouse

Investigational Site Number : 7240001, Salamanca

Froedtert Hospital & Medical College of Wisconsin Site Number : 8400004, Milwaukee

Mayo Clinic of Rochester Site Number : 8400005, Rochester

Investigational Site Number : 2030002, Brno

Investigational Site Number : 2030003, Ostrava - Poruba

City of Hope Site Number : 8400002, Duarte

Dana Farber Cancer Institute Site Number : 8400003, Boston